A 62-year-old woman with type 2 diabetes and obesity undergoes diagnostic hysteroscopy for postmenopausal bleeding. Histopathology reveals Grade 1 endometrioid adenocarcinoma, confined to the inner half of the myometrium on curettage. MRI shows no extrauterine disease. What is the most appropriate next step in management?

Explanation

## Clinical Context Early-stage (Stage IA) endometrial cancer with Grade 1 histology and myometrial invasion limited to the inner half requires surgical staging and treatment. This patient has no contraindications to surgery and represents a typical presentation for primary surgical management. ## Why Total Abdominal Hysterectomy with Bilateral Salpingo-Oophorectomy and Pelvic Lymph Node Dissection? **High-Yield:** Surgical staging is the gold standard for apparent early-stage endometrial cancer. The procedure includes: 1. **Total hysterectomy** — removes the primary tumor and uterus 2. **Bilateral salpingo-oophorectomy (BSO)** — removes ovaries (source of estrogen that may promote endometrial cancer) and allows assessment for metastases 3. **Pelvic lymph node dissection** — provides accurate staging; ~10% of clinically early-stage tumors have occult nodal disease **Key Point:** Lymph node status is the single most important prognostic factor in endometrial cancer and cannot be determined clinically or radiologically; surgical staging is mandatory. **Clinical Pearl:** Grade 1 tumors with inner-half myometrial invasion have a relatively favorable prognosis, but nodal assessment is still required to guide adjuvant therapy decisions. **Mnemonic:** TAHBSO + LND = **TAH** (Total Abdominal Hysterectomy) + **BSO** (Bilateral Salpingo-Oophorectomy) + **LND** (Lymph Node Dissection) — the "staging triple" for early endometrial cancer. ## Surgical Staging Algorithm for Endometrial Cancer ```mermaid flowchart TD A[Endometrial Cancer Diagnosed on Biopsy]:::outcome --> B{Clinically Early Stage?}:::decision B -->|Yes| C[MRI/CT for extrauterine disease]:::action C --> D{Extrauterine disease?}:::decision D -->|No| E[Surgical Staging Indicated]:::outcome D -->|Yes| F[Advanced disease: Neoadjuvant therapy]:::urgent E --> G[TAH + BSO + Pelvic LND]:::action G --> H[Pathological Staging]:::action H --> I{Risk Factors for Recurrence?}:::decision I -->|Low risk| J[Observation]:::outcome I -->|Intermediate/High risk| K[Adjuvant Radiation ± Chemotherapy]:::action ``` ## Why Not the Other Options? | Option | Why Incorrect | |--------|---------------| | Vaginal hysterectomy alone | Inadequate staging; does not allow lymph node assessment, which is essential for prognosis and treatment planning | | Neoadjuvant chemotherapy | Inappropriate for apparent early-stage disease; chemotherapy is for advanced/metastatic disease, not primary treatment of Stage IA tumors | | Radiation therapy alone | Does not remove the primary tumor; surgery is the cornerstone of treatment for early-stage disease | **Warning:** Do not omit lymph node dissection based on favorable histology or imaging — occult nodal disease occurs in ~10% of clinically early-stage tumors and changes management. ## Risk Stratification After Surgical Staging **Low-risk features:** Grade 1–2, no/superficial myometrial invasion, no LVSI → observation **Intermediate-risk features:** Grade 3 OR deep myometrial invasion OR LVSI → consider vaginal brachytherapy **High-risk features:** Non-endometrioid histology, advanced stage, nodal involvement → chemotherapy ± radiation